Month: July 2020

PARIS, July 15, 2020 (GLOBE NEWSWIRE) — Constellium SE (NYSE: CSTM) will host a conference call and webcast on Wednesday, July 22 at 10 a.m. (Eastern Daylight Time) to announce its second quarter 2020 results. The press release will be sent before market opening.The conference call will be hosted by Jean-Marc Germain, Chief Executive Officer, and Peter Matt, Executive Vice President and Chief Financial Officer.Details of the conference call, webcast and accompanying presentation will be available on the Constellium Investor Relations page at:https://www.constellium.com/financial-results-presentationsThe webcast can be accessed live at:https://edge.media-server.com/mmc/p/3h9sdq3sTo participate by telephone, please dial the following number and enter access code 6836118 to be connected to the Constellium earnings call: USA: 1 866...

SANTA ANA, Calif., July 15, 2020 (GLOBE NEWSWIRE) — Ducommun Incorporated (NYSE: DCO) (“Ducommun” or the “Company”) today announced that it plans to release the Company’s 2020 second quarter financial results after the market closes on July 30, 2020. Stephen G. Oswald, the Company’s chairman, president and chief executive officer, and Christopher D. Wampler, the Company’s vice president, interim chief financial officer and treasurer, and controller and chief accounting officer, will host a call that day, July 30, at 2:00 p.m. PT (5:00 p.m. ET) to review these results. To participate in the teleconference, please call 844-239-5278 (international 574-990-1017) approximately ten minutes prior to conference time. The participant passcode is 9433049. Mr. Oswald and Mr. Wampler will speak on behalf of the Company and anticipate...

WARREN, N.J., July 15, 2020 (GLOBE NEWSWIRE) — Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today that it will report results for the second quarter ended June 30, 2020 and provide a business update after market close on Tuesday, August 4, 2020.Management will host a conference call for investors at 8:00 a.m. ET on Wednesday, August 5, 2020. The conference call can be accessed by dialing (866) 417-5886 from the U.S. and (409) 217-8235 internationally, followed by the conference ID: 6069891.There will also be a simultaneous, live webcast available on the Investors section of the Company’s website at https://investors.aquestive.com/events-and-presentations. The webcast...

Providence Resources P.l.c. (“the Company”)Notification of Interest in Share CapitalProvidence Resources P.l.c. have been informed by Thomas Anderson that he holds 28,767,501 ordinary shares of €0.001 each in the capital of the Company representing 3.4% of the issued ordinary share capital.Simon BrettCompany Secretary15 July 2020End

Company Announcement No. 9/2020Copenhagen, 15 July 2020Attachment2009_Monthly update_June_2020_15_07_2020_UK

Selskabsmeddelelse nr. 9/2020København, 15. juli 2020Vedhæftet fil2009_Maanedlig_opdatering_juni_2020_15_07_20_DK

ORLANDO, Fla., July 15, 2020 (GLOBE NEWSWIRE) — Last month Colombian hemp and cannabis producer One World Pharma Inc. (OTCQB: OWPC) turned heads in the industry by naming NBA Hall of Famer Isiah Thomas its new Vice-Chairman and CEO as it begins to enter one of the most significant phases for the Company. As an executive of the highest order, Thomas’s new role in cannabis is significant not just for One World Pharma, but the industry.Over the past decade the cannabis industry has transformed beyond most anyone’s expectation. Legalization, expansion, and favorable public opinion have all blended into one enormous new commercial sector. And as an industry once operating in the shadows evolves so too will those officiating the opportunity.Each year we see new, highly talented leadership enter the space from an array of industries, bringing...

SAN FRANCISCO, July 15, 2020 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) affiliate QED Therapeutics announced today that the first child with achondroplasia has been dosed with the investigational medicine infigratinib, an orally available small molecule, that targets the overactivity of fibroblast growth factor receptor 3 (FGFR3) in the PROPEL 2 Phase 2 clinical trial. Achondroplasia is the most common cause of disproportionate short stature.¹“With preclinical evidence showing increased growth in the long bones, spine and cranial bones, including the base of the skull, there is the potential for infigratinib to help children with achondroplasia by decreasing the impact of serious medical complications,” said Professor Ravi Savarirayan, M.B., B.S., M.D., Ph.D., clinical geneticist and group leader of skeletal biology...

-Total product revenues of $17.2M, a 10% increase compared to Q2 2019 and 9% increase compared to Q1 2020--Trogarzo®net revenues up 13.2% and combined EGRIFTA®, EGRIFTA SV®net revenues up 7.3% over Q2 2019--Supply chain and product inventory remain unaffected by COVID-19 pandemic-MONTREAL, July 15, 2020 (GLOBE NEWSWIRE) — Theratechnologies Inc. (Theratechnologies, or Company) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today announced its financial results for the second quarter of fiscal 2020 ended May 31, 2020.“While the COVID-19 pandemic has presented many challenges to all communities and businesses worldwide, I am particularly proud of how our team has responded to ensure that we continue to achieve our business goals.  Despite these unprecedented times, we experienced growth for both Trogarzo® and...